Arcutis Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcutis Biotherapeutics (ARQT).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$29Upside to Avg. PT+21.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	Morgan Stanley	Vikram Purohit	PT Raise	Overweight	$34→$38
Aug 6, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$35→$38
Aug 6, 2026	Needham	Serge Belanger	PT Raise	Buy	$36→$40
May 7, 2026	Needham	Serge Belanger	Maintained	Buy	$36
Mar 2, 2026	Mizuho	Uy Ear	PT Cut	Outperform	$37→$35
Feb 27, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$34→$35
Feb 26, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$30→$35
Feb 26, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$30→$34
Feb 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$31→$36
Jan 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$31
Nov 28, 2025	Mizuho	Uy Ear	PT Raise	Outperform	$32→$37
Oct 30, 2025	Goldman Sachs	Richard Law	PT Raise	Neutral	$19→$29
Oct 28, 2025	Needham	Serge Belanger	PT Raise	Buy	$22→$30
Aug 7, 2025	Needham	Serge Belanger	PT Raise	Buy	$20→$22
Jul 25, 2025	Goldman Sachs	Richard Law	Initiate	Neutral	$18
May 23, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 9, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 3, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	—
Apr 3, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$19
Apr 3, 2025	Needham	Serge Belanger	Maintained	Buy	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $34 to $35.

Benzinga Newsdesk

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

PRO
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

PRO
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRONeedham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

PRONeedham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

PROMizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

PRO
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

PRO
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35